BioPharma Dive September 16, 2024
Warner Biddle, a former commercial executive at Gilead’s cancer cell therapy division, will take over as CEO, while ex-Kite leader Christi Shaw has joined Kyverna’s board.
Kyverna Therapeutics, a frontrunner in the push to develop cell therapies for autoimmune diseases, is switching CEOs only seven months after pricing one of the biotechnology industry’s largest initial public offerings of the year.
In a Monday statement, Kyverna said CEO Peter Maag has resigned from his role, as well as the company’s board, effective immediately. He’s been replaced by Warner Biddle, a longtime Genentech executive who has spent the last four years in senior commercial roles at Kite Pharma, Gilead’s cancer cell therapy division.
Christi Shaw, who ran Kite for several...
Today's Sponsors
Today's Sponsor